On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
The U.S. FDA's approval Thursday of BristolMyers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of ...
BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for BristolMyers shares. The analyst notes that given that many prior antipsychotic medications ...
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
Results that may be inaccessible to you are currently showing.